- Published: Friday March 31 2017 09: 04
The US pharmaceutical giant Johnson and Johnson has successfully bid for the Swiss company Actelion, according to a statement released Friday by Actelion.
Johnson and Johnson bought 73,25% of the share capital of Actelion in connection with its takeover bid, due to arrive Thursday.
In total 78,6 million shares were traded at the price proposed 280 dollars per share, bringing the total volume of shares held by the American group to 83,2 million, 77,20% of the capital and voting rights, according to provisional results published Friday by Actelion from its headquarters in Allschwil, near Basel.
The OPA is considered successful by both partners.
Shareholders still in possession of Actelion shares will have an additional period of ten trading days to make the Johnson and Johnson, the 6 21 until April.
The US giant also announced it has received approval of the Japanese and Israeli competition authorities and said he expected to have all the necessary regulatory approvals "in the second quarter 2017".
Earlier this year 2017, giant Johnson and Johnson Pharmaceuticals announced it would pay 30 billion dollars a 280 with respect to shareholders of the Swiss group to seize Actelion.
The transaction, approved by the board of directors of both companies, will be accompanied by a division of research activities in a new entity that will be floated.
The Actelion laboratory coveted regularly was the subject of takeover rumors. The group, founded in 1996 by French cardiologist John Paul Clozel has built a solid reputation around the Rare Diseases.